The CD133 antigen that we used to target colon cancer was positively expressed in human and mouse normal stomach tissues and the CAR133 construct we used to specifically target human CD133 antigen was derived from a murine scFv; however, it is important to analyze CAR133-NK92 cell safety in vivo. Here, PROM1 is linked to malignant colon neoplasm.